|
|
|
|
Medical News: European Researchers Look For New Ways To Fight Multi-Drug-Resistant Bacterial Infections
MRSA / Drug Resistance News Main Category: MRSA / Drug Resistance Also Included In: Infectious Diseases / Bacteria / Viruses email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public:...
|
|
|
European Researchers Look For New Ways To Fight Multi-Drug-Resistant Bacterial Infections
The Institute of Biotechnology and Biomedicine (IBB) belonging to Universitat Autnoma de Barcelona (UAB) is directing the AntiPathoGN European research project aimed at looking for new drug targets in pathogenic bacteria resistant to...
|
|
|
European Researchers Look For New Ways To Fight Multi-Drug-Resistant Bacterial Infections
The Institute of Biotechnology and Biomedicine (IBB) belonging to Universitat Autnoma de Barcelona (UAB) is directing the AntiPathoGN European research project aimed at looking for new drug targets in pathogenic bacteria resistant to...
|
|
|
Guidelines for the treatment of bacterial vaginosis: focus on tinidazole
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Therapeutics and Clinical Risk Management, 06/24/09 Print Save in My Library Free Full Text Dickey LJ et al.- Bacterial vaginosis (BV) is a complex...
|
|
|
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the
Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates in Adult Patients Hospitalized for Moderate to Severe CABP NEW YORK, June 19, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.(NYSE:FRX) announced today...
|
|
|
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the
3587 live jobs on PharmiWeb.com now 'We are extremely pleased with the results emanating from both Phase III CABP studies.These results represent a significant development milestone for ceftaroline,' said Dirk Thye, MD, President of...
|
|
|
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the
Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates in Adult Patients Hospitalized for Moderate to Severe CABP NEW YORK, June 19, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.(NYSE: FRX) announced today...
|
|
|
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the
Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates in Adult Patients Hospitalized for Moderate to Severe CABP NEW YORK, June 19, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.announced today positive results...
|
|
|
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the
Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates in Adult Patients Hospitalized for Moderate to Severe CABP NEW YORK, June 19, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.announced today positive results...
|
|
|
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the
Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates in Adult Patients Hospitalized for Moderate to Severe CABP NEW YORK, June 19, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.announced today positive results...
|
|
|
Forest Laboratories, Inc. (FRX) Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftarol
Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates in Adult Patients Hospitalized for Moderate to Severe CABP NEW YORK, June 19, 2009 /PRNewswire-FirstCall/ -- announced today positive results from two global multi...
|
|
|
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.(Nasdaq: KERX) today announced results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia,...
|
|
|
Medical News: Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results Of Zerenex (Ferric Citrate) For
Patient / Public: Health Professional: Article Opinions: Keryx Biopharmaceuticals, Inc.(Nasdaq: KERX) announced results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or...
|
|
|
Trius Announces Positive Results From Phase 2 Clinical Trial Of Torezolid In Patients With Complicated Skin An
Trius Therapeutics, Inc.announced results from its Phase 2 clinical trial evaluating the safety and efficacy of oral torezolid (TR-701), its investigational antibiotic for the treatment of severe complicated skin and skin structure...
|
|
|
Medical News: Trius Announces Positive Results From Phase 2 Clinical Trial Of Torezolid In Patients With Compl
MRSA / Drug Resistance News Main Category: MRSA / Drug Resistance Also Included In: Infectious Diseases / Bacteria / Viruses; Clinical Trials / Drug Trials email to a friend printer friendly view / write opinions rate article Current Article...
|
|
|
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.(Nasdaq: KERX - News) today announced results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or...
|
|
|
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.The top line efficacy and safety results from this Phase 2 study were submitted to the FDA, and discussed at a recent face to face meeting with the Division of...
|
|
|
PicksThatMove: Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) We have picks that move!
Hi and welcome to PicksThatMove.com where all you have to do is let us know what email address you want to receive our newsletter and then just watch the trade ideas we send you each week and track the incredible gains our current members...
|
